Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.74 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867407 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 | |
| SCHEMBL6487202 | 0.87 | CHRNA7 (0.80) | SMN1; SMN2CHRNA7PTGS2CA9 | |
| SCHEMBL6343133 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 | |
| SCHEMBL6342008 | 0.85 | CHRNA7 (1.00) | SMN1; SMN2CHRNA7PTGS2CA9 | |
| SCHEMBL6353957 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 | |
| SCHEMBL6341810 | 0.84 | CHRNA7 (0.85) | SMN1; SMN2CHRNA7PTGS2CA9 | |
| SCHEMBL6341682 | 0.83 | CHRNA7 (0.80) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 | |
| SCHEMBL3873219 | 0.83 | CHRNA7 (0.80) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 | |
| SCHEMBL6349530 | 0.82 | CHRNA7 (0.82) | SMN1; SMN2CHRNA7PTGS2CA9 | |
| SCHEMBL5698701 | 0.82 | MALT1 (0.80) | SMN1; SMN2CHRNA7CHRNB2CHRNA4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | claimed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| US-5760068-A | NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G.D. SEARLE & CO. (US) | 1998-06-02 | — | — | US | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | disclosed |
| US-5510496-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | SMN1; SMN2 4070/4885CHRNA7 2147/4885CHRNB2 1981/4885 |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | IRAK2, IRAK4, IRAK3 | SMN1; SMN2 3964/4885CHRNA7 3450/4885CHRNB2 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.